oxaliplatin + paclitaxel liposome

Oxaliplatin + paclitaxel liposome is an investigational combination chemotherapy regimen that includes oxaliplatin, a third-generation platinum-based antineoplastic agent, and paclitaxel formulated as a liposomal preparation. Oxaliplatin exerts its cytotoxic effect primarily through the formation of DNA crosslinks (both intrastrand and interstrand), leading to inhibition of DNA replication and transcription, ultimately resulting in cell death. The DACH moiety in oxaliplatin confers greater antitumor activity compared to earlier platinum agents and reduces cross-resistance with cisplatin or carboplatin[2][5]. Paclitaxel is an anti-microtubule agent that stabilizes microtubules, preventing their depolymerization during cell division, thereby inhibiting mitosis[1]. The use of a liposomal formulation for paclitaxel improves drug delivery by enhancing tumor targeting via the enhanced permeability and retention (EPR) effect while reducing systemic toxicity such as hypersensitivity reactions associated with conventional solvents[1]. This combination aims to leverage the complementary mechanisms of action for improved efficacy against solid tumors such as gastric cancer or colorectal cancer.

Other names

oxaliplatin and paclitaxel liposomeoxaliplatin plus liposomal paclitaxel